Becton, Dickinson and Company BDX
183.82
4.59
2.56%
as of 25 Sep
- Market cap
- $48.8B
- P/E
- 55.4×
Follow BDX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Becton, Dickinson and Company (BDX) Total debt
Becton, Dickinson and Company's total debt at the end of fiscal 2025 was $17.6B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $13.5B. Over the past ten years it has ranged from $10.6B (fiscal 2016) to $18.9B (fiscal 2018); the current reading is higher than 64% of that period. Becton, Dickinson and Company ranks 1st of 55 Medical Instruments & Supplies companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $17.6B | (1.78%) |
| FY2024 | $17.9B | 21.73% |
| FY2023 | $14.7B | 6.14% |
| FY2022 | $13.9B | (18.84%) |
| FY2021 | $17.1B | (0.66%) |
| FY2020 | $17.2B | (4.74%) |
| FY2019 | $18.1B | (4.30%) |
| FY2018 | $18.9B | 1.22% |
| FY2017 | $18.7B | 76.94% |
| FY2016 | $10.6B | (7.21%) |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $13.5B | (8.13%) |
| Mar 2026 | $14.7B | (13.06%) |
| Dec 2025 | $16.9B | (4.00%) |
| Sep 2025 | $17.6B | 0.51% |
| 42 more quarters | Free account |
Against its own ten years
Low $10.6B
High $18.9B
Ten-year median
$17.2B
Current reading's percentile
64
Total debt against peers
| Company | Total debt |
|---|---|
| BDX Becton, Dickinson and Company | $13.5B |
| MDLN Medline Inc. compare | $12.6B |
| BAX Baxter International Inc. compare | $9.5B |
| SOLV Solventum Corporation compare | $5.3B |
| ALC Alcon compare | $4.7B |
| RGEN Repligen Corporation compare | $551.0M |
| RMD ResMed Inc. compare | $399.4M |
| WST West Pharmaceutical Services, Inc. compare | $202.9M |
| ISRG Intuitive Surgical, Inc. compare | $94.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on BDX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement